Home Newsfeeds BTIG Downgrades T2 Biosystems to Neutral

BTIG Downgrades T2 Biosystems to Neutral

BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

byBenzinga Newsdesk

July 7, 2022

1 minute read

BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

JP Morgan Maintains Overweight on AGCO, Raises Price Target to $155

By Benzinga Newsdesk

December 13, 10:08 AM

JP Morgan analyst Tami Zakaria maintains AGCO (NYSE:AGCO) with a Overweight and raises the price target from $135 to $155.

AGCO

Bitcoin Falls Following PPI Data; Kaspa Emerges As Top Gainer

By Lisa Levin

November 15, 10:31 AM

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices trading below the $37,000 level on Wednesday. Ethereum (CRYPTO: ETH) also recorded losses, but remained above the key $2,000 mark this morning.

$CRO

Analyst Ratings

The Latest Analyst Ratings for Soho House

By Benzinga Insights

November 21, 2:00 PM

Analysts have provided the following ratings for Soho House (NYSE:SHCO) within the last quarter: Bullish Somewhat Bullish Indifferent…

SHCO

GENFIT Announces Publication In The Journal Of Hepatology On The Accurate Performance Of NIS2+ As A Screening Tool For The Enrollment Of Patients In MASH Clinical Trials

By Benzinga Newsdesk

December 6, 12:34 PM

The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH1 clinical trialsGrowing

GNFT

BTIG Downgrades T2 Biosystems to Neutral

Related Posts

JP Morgan Maintains Overweight on AGCO, Raises Price Target to $155

Bitcoin Falls Following PPI Data; Kaspa Emerges As Top Gainer

The Latest Analyst Ratings for Soho House

GENFIT Announces Publication In The Journal Of Hepatology On The Accurate Performance Of NIS2+ As A Screening Tool For The Enrollment Of Patients In MASH Clinical Trials